List view / Grid view
Drug Discovery Processes
article
Artificial intelligence in the world of drug discovery
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.
video
Video: Ethical and regulatory use of biospecimens in the EU
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
video
Video: Multiplex IHC and digital analysis for immuno-oncology
High content data derived for complex immuno-oncology research facilitates a deeper understanding of the tissue microenvironment.
article
Screening In-Depth Focus 2019
This in-depth focus discusses screening and the uses of phenotypic profiling in drug discovery. Also examined is the role that CRISPR/Cas9 gene editing and native mass spectrometry play.
whitepaper
Whitepaper: Cubis® II pharma compliant by design
Sartorius Cubis® II is designed to follow US FDA data integrity principles that require data to be accurate, legible, contemporaneous, original and attributable.
webinar
A high-throughput approach to developing T-cell immunotherapies
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
whitepaper
Whitepaper: TruBIOME™ increases mouse model reproducibility
Ensure reproducibility with TruBIOME™ - the unique approach to generating research model colonies, which allows you complete control over their microbiome, from conception to cohort delivery.
whitepaper
HCA: Phenotypic fingerprint of cellular function
High-content analysis app note: Phenotypic fingerprint of cellular function following gene editing by high-throughput imaging acquisition and analysis.
whitepaper
HCA Application note: New way of measuring synaptic function
High-content analysis: monitoring neurite morphology and synapse formation in primary neurons for neurotoxicity assessments and drug screening.
video
Video: High content imaging to examine RNA in cancer cells
Dr Kaylene Simpson, Peter MacCallum Cancer Center, describes their research using high content imaging to examine RNA in cancer cells.
video
Video: 3D Culture Screening
Michael Johnson and his team at Visikol talk about the work they do as a contract research organization on 3D Cell Cultures and how they utilize High-Content Analysis / Screening to generate insights.
product
Fast molecular interaction screening for all your projects
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
article
Drug discovery from the age of information to the age of intelligence
Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.
article
Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process
Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies,…